Abstract: The present disclosure is related to a microwave source. The microwave source may include a cathode heater and a thermionic emitter. The cathode heater may include a first component, and a second component enclosing at least a portion of the first component. The thermionic emitter may be configured to release electrons when the thermionic emitter is heated by the cathode heater. At least a portion of the second component of the cathode heater may be in contact with the thermionic emitter.

Abstract: Disclosed are a polyethylene glycol conjugate drug, and a preparation method therefor and the use thereof. Specifically, the present invention relates to a polyethylene glycol conjugate drug represented by formula A or a pharmaceutically acceptable salt thereof, a method for preparing the polyethylene glycol conjugate drug or the pharmaceutically acceptable salt thereof, an intermediate for preparing the polyethylene glycol conjugate drug or the pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the polyethylene glycol conjugate drug or the pharmaceutically acceptable salt thereof, and the use of the polyethylene glycol conjugate drug or the pharmaceutically acceptable salt thereof in the preparation of a drug.

Abstract: A method includes obtaining a first dataset associated with a first set of classes and a second dataset associated with a second set of classes, where the first and second datasets share features. The method also includes creating an aggregated dataset having a quality score for the second set of classes that satisfy a first threshold. Creating the aggregated dataset includes determining a first and second set of clusters based on the first and second datasets. The method includes determining a distance based on a record of the first set of clusters and a second record of the second set of clusters in a feature space. The method further includes determining a set of analysis scores based on the distance and generating an indication for a set of records associated with the set of analysis scores based on the set of analysis scores satisfying a second threshold.

Abstract: A polyethylene glycol conjugate drug synergist, a preparation method therefor, and use thereof, specifically relating to a polyethylene glycol conjugate drug synergist as shown in formula I or a pharmaceutically acceptable salt thereof, a preparation method for the polyethylene glycol conjugate drug synergist or the pharmaceutically acceptable salt thereof, an intermediate for preparing the polyethylent glycol conjugate drug synergist or the pharmaceutically acceptable salt thereof, a composition containing the polyethylene glycol conjugate drug synergist or the pharmaceutically acceptable salt thereof, and use of the polyethylene glycol conjugate drug synergist or the pharmaceutically acceptable salt thereof in preparation of a drug.

Abstract: The present invention relates to a polyethylene glycol conjugate medicament, a preparation method therefor and use thereof, and in particular relates to a polyethylene glycol conjugate medicament represented by formula (I) or a pharmaceutically acceptable salt thereof. The present invention also relates to a method for preparing the polyethylene glycol conjugate medicament or a pharmaceutically acceptable salt thereof, and an intermediate of the same, a pharmaceutical composition comprising the polyethylene glycol conjugate medicament or a pharmaceutically acceptable salt thereof, and use thereof in preparing a medicament.

Abstract: The present invention relates to a polyethylene glycol conjugate medicament, a preparation method therefor and use thereof, and in particular relates to a polyethylene glycol conjugate medicament represented by formula (I) or a pharmaceutically acceptable salt thereof. The present invention also relates to a method for preparing the polyethylene glycol conjugate medicament or a pharmaceutically acceptable salt thereof, and an intermediate of the same, a pharmaceutical composition comprising the polyethylene glycol conjugate medicament or a pharmaceutically acceptable salt thereof, and use thereof in preparing a medicament.

Abstract: A method and reverse debugger are provided for reversely debugging a program. The method includes: obtaining debugging information of the program as outputted by a compiler, the debugging information including information related to extended basic blocks of the program; in response to the program entering into reverse debugging, setting a reverse debugging checkpoint at an entry address of at least one extended basic block; in response to the program reaching a set reverse debugging checkpoint, storing information required by debugging that corresponds to the reverse debugging checkpoint; in response to receiving a set reverse debugging target breakpoint, making the program return to a reverse debugging checkpoint located before the reverse debugging target breakpoint and nearest to the reverse debugging target breakpoint, obtaining information required to be stored by the debugging stored at the reverse debugging checkpoint, and continuing to execute the program till the reverse debugging target breakpoint.

Abstract: A method and reverse debugger are provided for reversely debugging a program. The method includes: obtaining debugging information of the program as outputted by a compiler, the debugging information including information related to extended basic blocks of the program; in response to the program entering into reverse debugging, setting a reverse debugging checkpoint at an entry address of at least one extended basic block; in response to the program reaching a set reverse debugging checkpoint, storing information required by debugging that corresponds to the reverse debugging checkpoint; in response to receiving a set reverse debugging target breakpoint, making the program return to a reverse debugging checkpoint located before the reverse debugging target breakpoint and nearest to the reverse debugging target breakpoint, obtaining information required to be stored by the debugging stored at the reverse debugging checkpoint, and continuing to execute the program till the reverse debugging target breakpoint.